Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
We had reported the radiosynthesis of 2-deoxy-2-[18F]fluoroacetamido-D-glucopyranose, which was able to distinguish infection from inflammation in animal models. Furthermore, we developed new precursors with the same efficiency of [18F]fluoride incorporation under similar radiosynthesis conditions and also developed a high-performance liquid chromatography (HPLC) method for quality control of final [18F]FAG. Final specific activity using tosylate precursor was higher than using bromo precursor. Nevertheless, final specific activity and radiosynthesis yield were lower than previous radiosynthesis procedure therefore not suitable for clinical trials. Finally, the synthesis a new UDP-N-acetylglucosamine precursor was designed and is currently ongoing.
|